These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35577750)

  • 1. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum.
    Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Maxim Bruins H; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; A L M Kiemeney L; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
    Eur Urol Focus; 2022 Nov; 8(6):1627-1634. PubMed ID: 35577750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
    Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
    Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
    van Rhijn BWG; Hentschel AE; Bründl J; Compérat EM; Hernández V; Čapoun O; Bruins HM; Cohen D; Rouprêt M; Shariat SF; Mostafid AH; Zigeuner R; Dominguez-Escrig JL; Burger M; Soukup V; Gontero P; Palou J; van der Kwast TH; Babjuk M; Sylvester RJ;
    Eur Urol Oncol; 2021 Apr; 4(2):182-191. PubMed ID: 33423944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
    Hentschel AE; van Rhijn BWG; Bründl J; Compérat EM; Plass K; Rodríguez O; Henríquez JDS; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Scavarda-Lamberti A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Cohen D; Lunelli L; Cussenot O; Sheikh SE; Volanis D; Coté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Babjuk M; van der Kwast TH; Sylvester RJ
    Urol Oncol; 2020 May; 38(5):440-448. PubMed ID: 31704141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Sylvester RJ; Rodríguez O; Hernández V; Turturica D; Bauerová L; Bruins HM; Bründl J; van der Kwast TH; Brisuda A; Rubio-Briones J; Seles M; Hentschel AE; Kusuma VRM; Huebner N; Cotte J; Mertens LS; Volanis D; Cussenot O; Subiela Henríquez JD; de la Peña E; Pisano F; Pešl M; van der Heijden AG; Herdegen S; Zlotta AR; Hacek J; Calatrava A; Mannweiler S; Bosschieter J; Ashabere D; Haitel A; Côté JF; El Sheikh S; Lunelli L; Algaba F; Alemany I; Soria F; Runneboom W; Breyer J; Nieuwenhuijzen JA; Llorente C; Molinaro L; Hulsbergen-van de Kaa CA; Evert M; Kiemeney LALM; N'Dow J; Plass K; Čapoun O; Soukup V; Dominguez-Escrig JL; Cohen D; Palou J; Gontero P; Burger M; Zigeuner R; Mostafid AH; Shariat SF; Rouprêt M; Compérat EM; Babjuk M; van Rhijn BWG
    Eur Urol; 2021 Apr; 79(4):480-488. PubMed ID: 33419683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer.
    Olivier Bosset P; Neuzillet Y; Paoletti X; Molinie V; Botto H; Lebret T
    Urol Oncol; 2015 Jan; 33(1):20.e1-20.e7. PubMed ID: 25282704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Bladder and Upper Urinary Tract Follow-up Recurrence and Progression Rates of G1-2 Non-muscle-invasive Urothelial Carcinoma of the Bladder.
    Golabesk T; Palou J; Rodriguez O; Parada R; Skrobot S; Peña JA; Villavicencio H
    Urology; 2017 Feb; 100():145-150. PubMed ID: 27765584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Treatment Delays for Patients with Non-muscle-invasive Bladder Cancer.
    Ourfali S; Matillon X; Ricci E; Fassi-Fehri H; Benoit-Janin M; Badet L; Colombel M
    Eur Urol Focus; 2022 Sep; 8(5):1226-1237. PubMed ID: 34172421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
    Ma J; Roumiguie M; Hayashi T; Kohada Y; Zlotta AR; Lévy S; Matsumoto T; Sano T; Black PC
    Eur Urol Focus; 2024 Jan; 10(1):189-196. PubMed ID: 37442722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study.
    Bobjer J; Hagberg O; Aljabery F; Gårdmark T; Jahnson S; Jerlström T; Sherif A; Simoulis A; Ströck V; Häggström C; Holmberg L; Liedberg F
    Scand J Urol; 2022 Feb; 56(1):14-18. PubMed ID: 34623216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
    Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.
    van Rhijn BW; Burger M; Lotan Y; Solsona E; Stief CG; Sylvester RJ; Witjes JA; Zlotta AR
    Eur Urol; 2009 Sep; 56(3):430-42. PubMed ID: 19576682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.